Gilead R&D chief Nor­bert Bischof­berg­er is leav­ing in sur­prise ex­it, CEO re­vamps top sci­ence jobs

Af­ter a stretch of close to 30 years at Gilead $GILD, long­time R&D chief Nor­bert Bischof­berg­er is leav­ing the com­pa­ny. He’ll be step­ping out at the end of April, the lat­est in a whirl­wind se­ries of changes among the top sci­en­tists in bio­phar­ma.

Tak­ing his place will be John McHutchi­son, the cur­rent EVP of clin­i­cal re­search at Gilead. And An­drew Cheng is step­ping up as chief med­ical of­fi­cer. Both will re­port di­rect­ly to CEO John Mil­li­gan.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER